Gildan Activewear

$25.25 Outperform
Target: US$32.00
SymbolGIL
ExchangeNYSE
Trade Date-
Last Trade25.25
Change-0.69 - -2.66%
52-week Range16.32 - 37.55
Market Cap3.068B
Volume729405
Dividend Yield1.45
Price/Sales1.75
P/E Ratio25.81
This research is at least one month old. To access the latest research, please login or register now for a Market Research account.
Enter your Andrew Johns username.
Enter the password that accompanies your username.


GIL: F1Q12 Preview 2012-02-02
GIL: First Glance: F4Q11 Results 2011-12-01
GIL: F4Q11 Preview 2011-11-24
GIL: F3Q11 Results; Margins Speak Volumes 2011-08-05
GIL: Gildan F3Q11 Preview 2011-07-28
GIL: F2Q11 Results; Inflation in Perspective 2011-05-11
Gildan® is the leading activewear brand in the screenprint market in the U.S. and Canada. The brand is continuing to grow in Europe, Mexico and the Asia-Pacific region. The Company sells T-shirts, sport shirts and fleece as undecorated “blanks”, which are subsequently decorated by screenprinters with designs and logos. The Company is also one of the world’s largest suppliers of branded and private label athletic, casual and dress socks sold to a broad spectrum of retailers in the U.S. Gildan markets its sock products under a diversified portfolio of company-owned brands, including Gold Toe®, PowerSox®, SilverToe®, Auro®, All Pro®, GT®, and the Gildan® brand. The Company is also the exclusive U.S. sock licensee for the Under Armour® and New Balance® brands. In addition to socks, the Company is increasingly becoming a significant supplier of underwear and undecorated activewear products in the retail channel.
Consumer Cyclical Sector Wrap
Fox Business - 20 hours ago
The S&P 500 lost 0.4% while the Consumer Cyclical sector (XLY) showed little movement during trading today. As a proxy for the sector, the ETF tracked closer to the overall market today than over the past month.
Meryl Witmer Likes Viacom and Gildan
ValueWalk - 23 hours ago
By Jacob Wolinsky Meryl Witmer is a general partner at Eagle Capital Partners. She previously worked at Mutual Series with Max Heine and Michael Price.
Meryl Witmer of Eagle Capital Partners Likes Gildan Activewear, Viacom - Benzinga
Why Gildan Activewear's Earnings May Not Be So Hot
DailyFinance - May 11, 2012
By Seth Jayson, The Motley Fool Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company's economic output.
Gildan Announces Completion of Acquisition of Anvil
MarketWatch (press release) - May 9, 2012
MONTREAL, QUEBEC, May 09, 2012 (MARKETWIRE via COMTEX) -- Gildan Activewear Inc. (TOR:CA:GIL) (NYSE:GIL) today announced that it has completed the acquisition of Anvil Holdings, Inc. (Anvil), effective May 9, 2012.
Gildan Activewear Beats Estimates but Has a Big Earnings Drop
DailyFinance - May 7, 2012
By Seth Jayson, The Motley Fool Gildan Activewear (NYS: GIL) reported earnings on May 3. Here are the numbers you need to know. For the quarter ended April 1 (Q2), Gildan Activewear missed estimates on revenues and beat expectations on earnings per ...
Stonecap Securities Sets Gildan Activewear Price Target at $33.00 (GIL)
Junction Report - May 6, 2012
Equities research analysts at Stonecap Securities boosted their price target on shares of Gildan Activewear (NYSE: GIL) from $28.00 to $33.00 in a research note issued to investors on Friday.
Stock Analysts' Upgrades for May, 4th (AAWW, AHS, ALL, ANR, BLDP, CBB, CCOI ...
Junction Report - May 4, 2012
Atlas Air Worldwide Holdings, Inc. (NASDAQ: AAWW) was upgraded by analysts at Maxim Group from a “hold” rating to a “buy” rating.
UPDATE: Stonecap Reiterates Outperform Rating, Raises PT for Gildan Activewear
Benzinga - May 4, 2012
By Dwight Einhorn In a report issued earlier today, Stonecap Securities reiterated its Outperform rating for Gildan Activewear Inc. (NYSE: GIL) and raised its price target from $28.00 to $33.00.
Analyst Insights: Novavax, Abbott, Gildan, PVH, Rovi May 4th
Wall St. Cheat Sheet - May 4, 2012
By Derek Hoffman Abbott Laboratories (NYSE:ABT): RBC Capital expects an FDA panel evaluating Pfizer's (NYSE:PFE) rheumatoid arthritis drug to recommend that the agency approve the treatment, which will compete with Abbott's (NYSE:ABT) Humira.